Application of liquid biopsy in bone and soft tissue sarcomas: Present and future

Li, Xiaoyang; Seebacher, Nicole A.; Hornicek, Francis J.; Xiao, Tao; Duan, Zhenfeng

doi:10.1016/j.canlet.2018.09.012

Cited by 40 publications

(37 citation statements)

References 122 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Liquid biopsy may be highly advantageous, given the difficulty of recovering the bone sample for disease staging. In fact, it is a non-invasive and also time-saving approach; moreover, it may offer more precise and accurate information on early detection, therapeutic decisions, and response to therapy in OS [12,13].…”

Section: Discussionmentioning

confidence: 99%

Gathering Novel Circulating Exosomal microRNA in Osteosarcoma Cell Lines and Possible Implications for the Disease

Cuscino

Raimondi

Luca

et al. 2019

Cancers

View full text Add to dashboard Cite

One of the goals of personalized medicine is to understand and treat diseases with greater precision through the molecular profile of the patient. This profiling is becoming a powerful tool for the discovery of novel biomarkers that can guide physicians in assessing, in advance, the disease stage, and monitoring disease progression. Circulating miRNAs and exosomal miRNAs, a group of small non-coding RNAs, are considered the gold standard diagnostic biomarkers for human diseases. We have previously demonstrated that osteosarcoma-derived exosomes are able to influence crucial mechanisms inside tumor niches, inducing osteoclast differentiation, and sustaining bone resorption activity. Here we discovered, through Next-Generation Sequencing (NGS), eight novel microRNAs in three different osteosarcoma cell lines, and assessed the selective packaging into the exosomes released. We then investigated, as proof-of-principle, the presence of the novel microRNAs in osteosarcoma patient samples, and found that 5 of the 8 novel microRNAs were more present in circulating exosomes of osteosarcoma patients compared with the controls. These results raise a question: Could the 8 novel microRNAs play a role for osteosarcoma pathogenesis? Although still premature, the results are encouraging, and further studies with a validation in a larger cohort are needed.

show abstract

Section: Discussionmentioning

confidence: 99%

Gathering Novel Circulating Exosomal microRNA in Osteosarcoma Cell Lines and Possible Implications for the Disease

Cuscino

Raimondi

Luca

et al. 2019

Cancers

View full text Add to dashboard Cite

show abstract

“…For example, tissue biopsy is invasive and may result in some complications [14,15]. Furthermore, tissue biopsy only provides a snapshot of the genetic alterations in a single part of the tumor and does not reflect the dynamic changes of the tumor [16,17]. Tumor progression and response to chemotherapy or surgery also rely on radiological imaging investigation, but the imaging methods have limited sensitivity and specificity [17].…”

Section: Ivyspringmentioning

confidence: 99%

“…Invasive procedure [14,15] 2. Difficult to detect intratumoral and intertumoral heterogeneity with a single sample from a single site [16,17] 3. Possible clinical complications associated with tissue biopsy [14,15] 4.…”

Section: Advantagesmentioning

confidence: 99%

See 1 more Smart Citation

The new horizon of liquid biopsy in sarcoma: the potential utility of circulating tumor nucleic acids

Wei

Xing

et al. 2020

J. Cancer

View full text Add to dashboard Cite

The diagnosis, treatment and prognosis of sarcoma are mainly dependent on tissue biopsy, which is limited in its ability to provide a panoramic view into the dynamics of tumor progression. In addition, effective biomarkers to monitor the progression and therapeutic response of sarcoma are lacking. Liquid biopsy, a recent technological breakthrough, has gained great attention in the last few decades. Nucleic acids (such as DNA, mRNAs, microRNAs, and long non-coding RNAs) that are released from tumors circulate in the blood of cancer patients and can be evaluated through liquid biopsy. Circulating tumor nucleic acids reflect the intertumoral and intratumoral heterogeneity, and thus liquid biopsy provides a noninvasive strategy to examine these molecules compared with traditional tissue biopsy. Over the past decade, a great deal of information on the potential utilization of circulating tumor nucleic acids in sarcoma screening, prognosis and therapy efficacy monitoring has emerged. Several specific gene mutations in sarcoma can be detected in peripheral blood samples from patients and can be found in circulating tumor DNA to monitor sarcoma. In addition, circulating tumor non-coding RNA may also be a promising biomarker in sarcoma. In this review, we discuss the clinical application of circulating tumor nucleic acids as blood-borne biomarkers in sarcoma.

show abstract

“…Dabei gibt der Nachweis von Tumormarkern im Blut der Patientinnen und Patienten einen Hinweis auf die aktuelle Tumorlast und damit auf das Ansprechen von Therapien bzw. auf ein mögliches Wiederauftreten dieser Tumoren [17]. Demgegenüber ist eine gezielte Entwicklung eines Inhibitors gegen das Ewing-Translokationsprodukt bei Ewing-Sarkomen bislang noch nicht gelungen [7,20,24], wenngleich die präklinische Forschung dahingehende Ansätze nachdrücklich verfolgt [9,30]; erste kleinmolekulare Inhibitoren be-finden sich aktuell bereits in klinischer Testung (NCT02657005) [9,30].…”

Section: Ewing-sarkome Zeigen Charakteristische Translokationenunclassified

Gibt es eine Magic Bullet für Sarkome?

et al. 2019

View full text Add to dashboard Cite

Personalisierte Therapien von Tumorerkrankungen zielen darauf ab, spezifische überlebenswichtige Mechanismen eines Tumors bei bestmöglicher Schonung des restlichen Organismus medikamentös zu unterbinden. Maßgeschneiderte Therapeutika sind mittlerweile für viele Tumorerkrankungen im Einsatz. Damit stellt sich die Frage, inwieweit diese neuen Therapieformen auch für maligne Tumoren des Stütz-und Bewegungsapparates relevant werden.

show abstract

Application of liquid biopsy in bone and soft tissue sarcomas: Present and future

Cited by 40 publications

References 122 publications

Gathering Novel Circulating Exosomal microRNA in Osteosarcoma Cell Lines and Possible Implications for the Disease

Gathering Novel Circulating Exosomal microRNA in Osteosarcoma Cell Lines and Possible Implications for the Disease

The new horizon of liquid biopsy in sarcoma: the potential utility of circulating tumor nucleic acids

Gibt es eine Magic Bullet für Sarkome?

Contact Info

Product

Resources

About